Levodopa and the dopamine receptor D1-Hippo/yes-associated protein axis: A novel therapeutic avenue for liver fibrosis.
Levodopa and the dopamine receptor D1-Hippo/yes-associated protein axis: A novel therapeutic avenue for liver fibrosis.
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
Hangzhou, CN · Author affiliation
Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, Zhejiang Province, China.Location evidence
London, GB · Author affiliation
Department of Metabolism, Digestion and Reproduction, Imperial College London, London SW7 2AZ, United Kingdom.Location evidence
A plain-language reading has not been prepared for this paper yet.
Original abstract
Liver fibrosis remains a major global health challenge with limited therapeutic options. In their recent study, Wang et al report that levodopa, a dopamine precursor widely used in Parkinson's disease, significantly attenuates carbon tetrachloride-induced liver fibrosis in rats by enhancing dopamine receptor D1 expression and activating the Hippo signaling pathway, leading to phosphorylation and inactivation of yes-associated protein 1. This discovery links G-protein-coupled receptor signaling to Hippo pathway regulation in hepatic fibrosis. The work highlights the dopamine receptor D1-Hippo/yes-associated protein 1 axis as a promising antifibrotic mechanism and introduces levodopa as a potential repurposing candidate for chronic liver disease. With its established safety and affordability, levodopa offers a rapidly translatable strategy that warrants validation in human tissues and diverse fibrosis models. Here, we place these findings in the broader context of G-protein-coupled receptor regulation of hepatic stellate cell activation, discuss translational opportunities for levodopa in liver fibrosis, and propose future directions to validate this pathway across disease models and clinical settings.